Dactolisib

Drug Profile

Dactolisib

Alternative Names: BEZ-235; NVP-BEZ-235

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Novartis
  • Developer CSL; Memorial Sloan-Kettering Cancer Center; Novartis
  • Class 3-ring heterocyclic compounds; Acetonitriles; Antineoplastics; Benzenesulfonates; Imidazoles; Nitriles; Quinolines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; 3 phosphoinositide dependent protein kinase 1 inhibitors; Apoptosis stimulants; Immunostimulants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza virus infections
  • Discontinued Breast cancer; Glioblastoma; Haematological malignancies; Non-small cell lung cancer; Pancreatic cancer; Perivascular epithelioid cell tumours; Prostate cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 09 Mar 2016 Novartis terminates a phase II trial in Pancreatic cancer (neuroendocrine tumours, late-stage disease) in USA, Italy, the Netherlands, Spain, United Kingdom, France, Poland, Switzerland and Russia (NCT01628913)
  • 01 Feb 2016 Discontinued - Phase-I/II for Renal cell carcinoma in USA (PO) (NCT01453595)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top